Identification of Drug Characteristics for Implementing Multiregional Clinical Trials Including Japan.

Autor: Rokuda M; Global Regulatory Science, Gifu Pharmaceutical University, Gifu, Japan; Japan-Asia Clinical Development 1, Development, Astellas Pharma Inc., Tokyo, Japan. Electronic address: mitsuhiro.rokuda@astellas.com., Matsumaru N; Global Regulatory Science, Gifu Pharmaceutical University, Gifu, Japan., Tsukamoto K; Global Regulatory Science, Gifu Pharmaceutical University, Gifu, Japan.
Jazyk: angličtina
Zdroj: Clinical therapeutics [Clin Ther] 2018 Feb; Vol. 40 (2), pp. 284-295. Date of Electronic Publication: 2018 Feb 01.
DOI: 10.1016/j.clinthera.2017.12.010
Abstrakt: Purpose: Multiregional clinical trials (MRCT) are a standard strategy used to improve global drug approval efficiency and the feasibility of clinical trials. Japan is the world's third largest drug market with a unique health care system, making it a key inclusion as an operational region for MRCT (MRCT-JP) for global drug development. We aimed to identify the factors required for efficient drug development by comprehensively reviewing the clinical trials of drugs approved in Japan to identify the factors associated with whether or not MRCT-JP is implemented.
Methods: We surveyed the review reports and summaries of application data published by the Pharmaceuticals and Medical Devices Agency. We identified drugs for which the clinical trial data package included MRCT-JP and selected the same number of drugs for which the clinical trial data package did not include MRCT-JP from the most recent survey period for comparison. We also examined other publication information, in addition to the review reports, as necessary. The influence of each explanatory variable was analyzed by logistic regression analysis, with whether or not MRCT-JP was implemented as the explanatory variable. Statistical significance was set at 5%.
Findings: In the survey period up to September 2017, 165 drugs developed with MRCT-JP were approved for manufacture and sale in Japan. "Respiratory system," "inhalation," "biological drug," and "under review" evaluation status for the United States, European Union, and other areas, "approved" evaluation status for the United States, "new ingredients," "priority review," "non-Japanese firm," and "Top 1-10" and "Top 11-20" drug sales rankings for pharmaceutical companies were identified as potential factors leading to the implementation of MRCT-JP. In contrast, "general anti-infectives for systemic use," "various," "external," "chemical compound," "unsubmitted" evaluation status for both the United States and European Union, and "Top 51+" drug sales rankings were potential factors for not implementing MRCT-JP.
Implications: Therapeutic classification and agent type, in addition to capital type and United States and European Union evaluation status suggested by a previous study, were associated with implementing MRCT-JP. It is important to determine the best way to utilize MRCT-JP to maximize the value of products. Our findings were based on successful cases and may therefore be helpful for designing clinical development plans. Appropriate use of MRCT-JP will improve productivity in the pharmaceutical industry.
(Copyright © 2018 Elsevier HS Journals, Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: